An observational study in Human Anaplasmosis, sponsored by University Hospital, Strasbourg, France. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-31.
Sponsored by University Hospital, Strasbourg, France · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Anaplasmosis is a bacterial infection caused by the intracellular bacterium Anaplasma phagocytophilum and transmitted by ticks. This bacterium is present in approximately 1% of ticks in Alsace. This infection is responsible for clinical manifestations that are most often mild, including fever, headache, and myalgia, occurring 2 to 3 weeks after a tick bite. However, this infection can be accompanied by potentially serious or even fatal complications, including severe cytopenias, acute respiratory distress syndrome, septic shock, severe neurological disorders, hemorrhagic manifestations, macrophage activation syndrome, and multiple organ failure. Mortality is variable and appears to be higher in American studies, where it is around 4%. Treatment is well-established and relies on doxycycline, which is highly effective. Although a few cases have been described in France, these are mostly isolated cases or short series of cases, whereas Belgium, Poland, and Slovenia have reported numerous cases. Thus, there is a lack of data on French cases, and given that Alsace is in a region with a high prevalence of tick-borne diseases, data is needed to better understand the epidemiology and to better identify suspected cases in order to provide appropriate care.
81 studies on the registry are indexed under Cytopenia; 25 are open to participants now.
This study's planned enrollment of 100 is below the median of 202 across 15 observational studies indexed under Cytopenia.
Browse Cytopenia studies →University Hospital, Strasbourg, France is the lead sponsor of 1,000 studies on the registry; 359 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Adult subjct (≥18 years) having a PCR-confirmed infection of Anaplasma
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
- Refusal to participate in the study
Mortality of cases of human anaplasmosis in Alsace
Time frame: Up to 12 years
Started Oct 2024 (actual). Primary completion is estimated for Feb 2026, 16 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Hospital, Strasbourg, France →